Highlights

  • Nanosonics Limited (ASX:NAN) reported AUD 203.9 million Revenue for FY26.
  • The global trophon installed base reached 39,230 devices.
  • Recurring revenue totalled AUD 149.2 million for the year.
  • The company continued preparations for commercialisation of its CORIS system.

Nanosonics Limited develops infection-prevention technology used to reprocess medical devices, including ultrasound probes. Shares in Nanosonics (ASX:NAN) traded at AUD 2.91 on November 17, 2026, declining 1.02% during the session. Its FY26 reporting showed revenue growth, an expanding trophon installed base and continued expenditure on the CORIS endoscope-cleaning platform, creating different financial dynamics across its established and developing products.

trophon and a Broader Reprocessing Portfolio

The company’s trophon system provides automated high-level disinfection for ultrasound probes. Sales include new devices, upgrades, consumables and service arrangements, with installed devices generating ongoing Demand for related products. The CORIS system is a separate platform aimed at endoscope cleaning. These products address infection-control tasks undertaken by hospitals and healthcare providers, where purchasing decisions and workflow adoption can involve technical validation and institutional procurement.

Device Placements and Commercial Progress

During FY26, Nanosonics (ASX:NAN) recorded 4,230 global trophon device placements, a 9% increase. The figure included 2,230 new installed-base units and 2,000 upgrades. Its cumulative installed base rose 6% to 39,230 devices. Upgrades replace or refresh equipment already used by customers, while additions expand the population of installed units. Both streams influence device revenue, but additions are especially relevant to the longer-term consumables and service base.

The company continued work on the commercial introduction of CORIS, which targets a different medical reprocessing procedure from trophon. CORIS Investment should be distinguished from the financial performance of the established ultrasound-probe disinfection business. Regulatory clearance and the launch programme do not in themselves establish adoption volumes or future earnings; those will depend on customer deployment, operational experience and purchasing decisions.

FY26 Revenue and Earnings

For the year ended June 30, 2026, Nanosonics (ASX:NAN) reported revenue of AUD 203.9 million, an increase of 2.7%. On a constant-currency basis, growth was approximately 6.5%. Recurring Revenue reached AUD 149.2 million, up 2% in reported currency, reflecting consumables and service activity. The distinction between reported and constant-currency growth is important because overseas Business activity is translated into Australian dollars for the group accounts.

Gross profit was AUD 156.8 million, with a reported gross Margin of 76.9%. Earnings before interest and tax totalled AUD 16.0 million, while net profit after tax was AUD 17.8 million. Cash and cash equivalents at year end were AUD 155.2 million. The company identified trophon-only EBIT of AUD 50.6 million; this is a business-level measure and should not be mistaken for group EBIT after expenditure across corporate activities and newer product initiatives.

Product Adoption Risks and Next Measures

For Nanosonics (ASX:NAN), purchasing cycles, infection-control protocols, distributor execution and competition affect new device placements. Recurring consumables revenue depends partly on continued use of installed devices. CORIS adds costs and commercial uncertainty during its introduction, while foreign-exchange movements may affect reported results. Subsequent disclosures on system placements, consumables growth, operating expenditure and CORIS rollout progress will be more informative than regulatory milestones alone.

Key Insights

Nanosonics (ASX:NAN) exited FY26 with an installed trophon base of 39,230 devices, recurring revenue of AUD 149.2 million and group net profit of AUD 17.8 million. CORIS represents a separate development and commercialisation effort. Its eventual financial contribution remains subject to evidence from real-world customer adoption and later financial reporting.